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Comparison of P53 Protein Overexpression 
With P53 Mutation In Bladder Cancer: 
Clinical and Biologic Aspects
J acqueline A.M. Vet, P ierre Paul B ringuier, H. E wout S chaafsm a, J . A lfred W it je s ,
F rans M. J. D ebruyne, and Jack A. S chalken
Department of Urology, University Hospital Nijmegen, and the Department o f Pathology, 
Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
BACKGROUND: Alterations of the tumor suppressor gene p53 are know n to occur in  bladder cancer. 
Although p53 overexpression is associated w ith mutation of the p53 gene, a substantial discrepancy  
between molecular genetic alteration in p53 and overexpression of the protein  has been  found.
EXPERIMENTAL DESIGN: Tumor specimens of 39 bladder cancer patients w ere im m unohistochem i- 
cally analyzed for p53 overexpression, and the results were compared w ith the presence of a m utation  
as assessed by single strand conformation polymorphism (SSCP) and direct sequencing* Both clin ical 
and biologic aspects were studied.
RESULTS: A significant correlation between p53 overexpression and poor survival in  the w hole group 
studied was found (p < Ö.01), No association betw een p53 overexpression and decreased survival was 
found for invasive tumors in contrast w ith other studies. D ifferences in  treatm ent of the patients and  
different Ab and scoring systems used might explain these differences. In our study, the Kaplar-Meier 
curves showed the same result for p53 overexpression and p53 mutation, w hen the w hole group and  
the invasive tumors were studied. However, in the group of superficial tum ors, w hich was unfortu­
nately too small for statistical analysis, we found p53 overexpression in  three tum ors, and no p53 
m utations were found. A good concordance betw een p53 mutation and p53 overexpression w as found  
(p < 0.02). However, two out of eight tumors w ith an SSCF-proven p53 m utation show ed no p53 
immunoreactivity, probably as a result of loss of the nuclear localization signal. Twenty three percent 
(7/31) of the tumors showed p53 over expression without any sign of a m utation.
CONCLUSIONS: Our results indicate that, despite a good concordance betw een p53 m utation and p53 
overexpression, there is no direct causal relationship betw een m utation and protein  accum ulation. 
Apparently, other events than mutation can trigger p53 stability.
Additional key words: Prognostic value, SSCP, Immunohistochemistry, TCC.
The tumor suppressor gene p53 is located on chro­
mosome 17pl3.1 and encodes a 53~kD nuclear phos- 
phoprotein with specific DNA binding properties.
Chromosomal losses of 17pl3 occur during tumor pro­
gression in a variety of human tumors (1). In bladder 
cancer, loss of 17pl3 is associated with high grade 
tumors and invasive disease (2, 3). In accordance with 
the classic tumor suppressor theory, the loss of het­
erozygosity (LOH) of 17pl3 is often accompanied by a 
mutation of the remaining allele (4). In bladder cancer, 
p53 mutations correlate with grade and stage (5-7) 
and probably play a role in the progression of this 
disease.
Wild-type p53 acts as a cell cycle control protein at 
the level of Gl-to S-phase transition (8). If DNA dam­
age occurs, p53 levels rise and block cells in the 
Gl-phase. The DNA damage can subsequently be elim­
inated either by DNA repair or by initiation of apopto-
sis (9), The up-regulation by p53 of p21, an inhibitor of 
G l cyclin-dependent kinases, appears to be responsible 
for p53-mediated growth arrest (10). Recently, Smith et 
al. showed that Gadd45, which is up-regulated by p53, 
probably serves as a link between the p53-dependent 
cell cycle checkpoint and DNA repair (11). p53 seems to 
function through modulation of transcriptional activ­
ity, enhancing the expression of genes containing p53- 
binding sites and interacting with a variety of tran­
scription factors to inhibit the expression of other 
genes (12, 13). Cells that lose this wild-rtype p53 func­
tion fail to show growth arrest if DNA damage occurs, 
which can lead to replication of incorrect DNA, result­
ing in genetic instability (14, 15). In addition to muta­
tion, loss of wild-type p53 function can be the result of 
complexing with viral oncoproteins, e.g., simian virus 
40 (SV 40), large T Ag (16, 17), adenovirus 5 Elb  
protein (18) and E6 protein of human Papillomavirus
837
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16 and 18 (19). The cellular oncoprotein mdm2 also 
interacts directly with p53 and functionally inactivates 
it (20).
The occurrence of p53 mutations leads to conforma­
tional changes of the protein, resulting in a prolonged 
half-life and subsequently in accumulation of the pro­
tein (21). The extended half-life of the protein is the 
basis for immunohistochemical detection of p53. Al­
though there is a good concordance between p53 over­
expression and mutation of the p53 gene, several 
studies have shown a considerable discrepancy be­
tween molecular genetic alteration in p53 and overex­
pression of the protein (22-25). In this study, we 
compared the immunohistochemical detection of p53 
overexpression with p53 mutation as assessed by 
single-strand conformation polymorphism (SSCP).
EXPERIMENTAL DESIGN 
T u m o r  Sp e c im e n s
Twenty-three snap frozen, superficial bladder carci­
nomas (pTa-pTl) and 24 muscle-invasive bladder car­
cinomas (pT s  2) obtained from 45 patients were used 
for SSCP analysis, as described previously (7). The 
transitional cell carcinomas were classified according 
to the World Health Organization criteria (26). For 
immunohistochemistry, the same specimens were in­
vestigated, with the exception of two superficial and 
two invasive carcinomas that could not be analyzed 
because of poor quality of the frozen tissue. Moreover, 
the two squamous cell carcinomas were removed from 
this study because of their different pathologic back­
ground. The clinical and pathologic data are shown in 
Table 1. Genomic DNA was extracted from step- 
sectioned tumors (>70% tumor cells) using a method 
described by Miller and coworkers (27).
I m m u n o h is t o c h e m is t r y
Cryostat sections (5 ¡jlm) were dried overnight. Tissue 
sections were fixed in acetone for 10 minutes and then 
incubated overnight at 4° C with the mouse mAb DO-7 
(Novocastra, Newcastle upon Tyne, UK) at a dilution of 
1:100. This Ab recognizes both wild-type and mutant p53. 
Sections were subsequently incubated for 30 minutes with 
biotinylated sheep anti-mouse lg Ab (1:200, Amersham, 
Buckinghamshire, UK) and then incubated for 30 minutes 
with streptavidin biotinylated-horseradish peroxidase com­
plex (1:100, Amersham). After washing with PBS, 3,3'- 
diaminoberizidine (Sigma Chemical Company, St. Louis, 
MO) was used as a chromogen, and hematoxylin was used 
for counterstain.
Analysis of the immunohistochemical results was 
performed by two investigators (J.V., P.P.B.). The 
pattern of p53 nuclear overexpression was classified in 
four categories by estimating the percentage of stained 
tumor cells: —, no cells positive; +, 1 to 10% positive 
tumor cells; + + , 10 to 50% positive tumor cells; and 
+ + + , > 50% positive tumor cells. Cytoplasmic stain­
ing was not scored.
PCR-SSCP
PCR-SSCP analysis (28) was performed to investi­
gate p53 mutations in exons 5 to 8. The intron primers
for amplification of exons 5 to 8 were: exon 5: S: 5' tea 
ctt gtg ccc tga ctt 3' and AS: 5' gag gaa tea gag gcc tgg 
3'; exon 6: S: 5' gag acg aca ggg ctg gtt 3' and AS: 5' gag 
acc cag ttg caa acc 3'; exon 7: S: 57 cca agg ege act ggc 
ctc 3' and AS: 5' gag gca age aga ggc tgg 3'; and exon 8: 
S: 5' cet tac tgc ctc ttg ette 3' and AS: 5' tga ate tga ggc 
ata act 3'.
Genomic DNA (250 ng) was subjected to 35 cycles of PCR 
(95, 57, and 72° C for 0.5, 2, and 1.3 minutes, respectively). 
Exons 5,6, and 8 were amplified in 50 ¡A containing: 50 mM 
KC1, 10 niM Tris-HCl (pH 8.8), 1.75 mM MgCl2, 250 /xm
deoxynucleotide triphosphates, 10 pmol of each 5' end- 
labeled primer, and 1.5 U of Taq polymerase (Perkin 
Elmer/Cetus, Norwalk, CT). Exon 7 was amplified in the 
same buffer containing 1.5 ihm  MgCl2.
Five microliters of the PCR product was diluted in 15 
fjl of loading buffer (96% formamide, 20 mM EDTA, 
0.05% bromophenol blue, and xylene cyanol), boiled for 
3 minutes, and then quenched (10 minutes) on ice 
before loading (2 /xl/lane). Each sample was applied to 
a 5% polyacrylamide (49:l)/Tris-Borate EDTA (0.5 X) 
gel with and without 10% (v/v) glycerol. Subsequently, 
electrophoresis was performed at room temperature for 
16 hours at 6 or 3 W, respectively.
S e q u e n c e  A nalysis
Direct sequencing of the double-stranded PCR prod­
ucts that showed a shift on the SSCP gels was per­
formed as described previously (29). Amplified PCR 
products were purified using the magic PCR-preps 
DNA purification system (Promega, Madison, WI). The 
PCR primers were used for sequencing in the dsDNA 
cycle sequencing system (Life Technologies, Inc). Elec­
trophoresis was performed on 6% polyacrylamide 
(19:1) gels containing 7 M ureum.
S tatistical  A nalysis
The Kaplan-Meier method was used to estimate 
survival probability as a function of time. Differences 
in survival were analyzed by a log-rank test. The x2 
test (with Yates correction if relevant) was used for the 
other correlations.
RESULTS AND DISCUSSION 
Im m u n o sta in in g  P a tter n s
The DO-7 staining patterns of the four groups are 
shown in Figure 1. We defined a tumor as p53 positive 
if more than 10% of the tumor cells showed nuclear p53 
expression. Of the 41 tumors studied, 13 showed p53 
overexpression.
C orrelation  B e tw e e n  T um or  G ra de /S tage a n d  p 53  
Ov er ex pr essio n
p53 overexpression was found in 9% of the Grade 1, 
23% of the Grade 2, and 60% of the Grade 3 tumors. 
Overexpression of p53 was found in 16% of the super­
ficial tumors and in 50% of the invasive tumors (p 
0.05) (Tables 2, 3). p53 mutations found by SSCP 
analysis showed a high correlation with both increas­
ing grade (p < 0.001) and stage (p < 0.001) (7).
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Table 1. P53 Overexpression, Clinical and Pathologic Data for Each Patient
Case
Age
(years) Stage/Grade P53 Immunopositività Recurrences
Survival
(months) Treatment
1 77 A/1-2 -f. NO 31 TURT
2 81 A/1 — A/2, 8 months >65 TURT
3 77 A/1 — NO >58 TURT
4 73 A/1 — NO >55 TURT,CH
5 66 A/3 4-4- A/2, 8 months 23 TURT,CT,R,CH
6 55 A/1-2 — A/2, 4 months >68 TURT,BCG,CT
6REC. A/1-2
w £
7 54 A/1 NO >46 TURT
8 50 A/1 • A/1, 8 months >84 TURT,BCG,CH
9 88 A/2 — NO 52 TURT,CH
10 50 A-1/2 + + NO >69 TURT
11 68 A-1/1 — 1/2, 4 months >37 TURT
12 75 1/3 — A/2, 6 months >72 TURT,BCG
13 92 1/2 M*| •* A/2, 11 months 73 TURT,CH
14 62 1/2 — NO >40 TURT,CPI
15 58 1/2 + A/1, 9 months >50 TURT,BCG
16 71 1/1 ------ A/2, 4 months >75 TURT
17 79 1/2 A/3, 3 months 49 TURT,CH
17REC. A/3
18 77 1/2 + NO >58 TURT, CH
19 72 1/2 + A/2, 6 months >44 TURT,CH,BCG
20 81 2/2 — 9 TURT
21 73 2/2 + 8 TURT,CH,CT
22 53 2/3 + >50 TURT, R, IRIDIUM
23 79 2/3 4 CT
24 81 2/2 -- 6 TURT
25 53 2/3 + 4- 7 TURT,CH
26 70 2/3 4- 4- 3 TURT,CH
27 47 2/3 — 8 TURT,CH
28 67 S2/3 — •t >20 TURT,CH,R
29 72 ; 5:2/3 H—1—H >85 TURTjCT
30 79 ^2/3 + 10 TURT,CT
31 59 &2/3 4- -f- 3 TURT,R
32 73 2-3/3 4- 4- 2 TURT,R
33 68 2-3/3 2 TURT
34 63 3/3 4* 4* 5 TURT,R
35 74 3/3 4- 4  + 10 CT.CH
36 74 3B/2 4- 4* >39 CT
37 80 3B/3 ■ ■ >53 TURT,R,CT
38 44 4/3 — 29 TURT,CT
39 82 4/2 — 5 TURT
CH, chemotherapy; CT, cystectomy; R, radiotherapy; TURT, transureter al resection of the tumor; SCC, squamous cell carcinoma; REC., 
recurrence; (P), polymorphism codon 213.
"Number of positive cells: - ,  10%; +, 1-10%; 4-4-, 10-50%; 4-4-4-, >50%.
Correlation  B etw een  p 53 Ov erexpr essio n  a n d  
S urvival
The survival according to p53 overexpression is 
shown in Figure 2, For the whole group, a shorter 
survival time of patients with p53 overexpression 
was observed (^2, 8 .0 0 ,  p  < 0 , 0 1 ,  Fig. 2a). Although 
statistical analysis was not possible because of the 
small number studied, we observed a shorter sur­
vival time for patients with superficial bladder
Within the group with invasive disease, no signif­
icant difference in survival time between the pa­
tients with and without p53 overexpression was 
seen (Fig. 2c).
C o m pa r iso n  B e t w e e n  p 5 3  Ov e r e x p r e s s io n  w ith  p 53  
M u t a t io n s  F o u n d  by PCR-SSCP
The overall comparison of p53 mutations analyzed 
by PCR-SSCP and p53 overexpression assessed by 
immunohistochemistry (IHC) is shown in Table 4, The 
sensitivity of IHC, defined as percentage of IHC- 
positive tumors among tumors with identified muta­
tion, was 75%. The specificity of IHC, defined as 
percentage of IHC-negative tumors among neoplasms 
without a p53 mutation, was 77%. Despite the good 
concordance between p53 mutation and p53 protein 
overexpression (p < 0.02), 23% (7/31) of the tumors 
without a p53 mutation as assessed by SSCP analysis 
showed p53 overexpression. Table 5 shows the eight
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Fto. 2. Kaplan-Meior survival curves of bladder cancer patients 
according to the presence or absence of overexpression of the p53 
protein. A  All patients (p < 0.01, log rank test), B Patients with 
superficial (pTa,pTl) tumors (not significant). C Patients with mus­
cle invasive disease (not significant),
alterations. We chose a cut-off of 10% p53 positive 
tumor cells for p53 overexpression. The appearance of 
occasionally stained cells in tumors, which we scored 
as negative, can be explained by the existence of clones 
of cells with a p53 mutation or by the occurence of 
a genotoxic event that raises levels of wild-type 
p53 protein in normal cells, resulting in cell cycle 
arrest (30, 31). More detailed examination of microdis­
sected focally stained areas by means of mutation 
analysis (SSCP) has to be performed to address this 
problem and to check the biologic importance of this 
phenomenon.
The overexpression of p53 as assessed by IHC corre­
lates with grade and stage (p <  0.05), However, corre­
lation between mutations in the p53 gene as deter­
mined by SSCP analysis and grade and stage was 
higher (p <  0.001) (7). In concordance with other IHC 
studies (32, 33), we demonstrated that p53 overexpres­
sion is an unfavorable prognostic factor for bladder 
cancer patients (p < 0.01). No association between p53 
overexpression and decreased survival was found for 
invasive tumors, in contrast with other studies. Differ­
ences in the treatment of the patients and the different 
Ab and scoring systems used might explain these 
differences. Esrig and coworkers (33) showed that p53 
overexpression is a significant predictor of tumor pro­
gression if the disease is confined to the bladder. 
However, no association between p53 overexpression 
and tumor progression was found if the disease was not 
confined to the bladder (pT3b, pT4), Because of the 
relatively small number in our study, we cannot com­
pare these two groups. The results of our study show 
that p53 overexpression has no additional prognostic 
value over stage, whereas for this same group of 
patients, we found that E-cadherin may have addi­
tional prognostic value over stage (34). Apparently, 
other mechanisms can lead to tumor progression, and 
they may override or bypass the function of p53.
The Kaplan-Meier curves showed the same result for 
p53 overexpression and p53 mutation (7) when the 
whole group and the invasive tumors are studied. Por 
superficial tumors, however, three patients showed 
p53 overexpression without a mutation confirmed by 
SSCP analysis. Although this was not statistically 
significant, a trend was observed toward worse sur­
vival for the patients showing p53 overexpression. This 
was not observed when p53 mutations were analyzed, 
because we found no mutations at all in the group of 
superficial tumors. In high grade pTl tumors, p53 
overexpression had predictive value for progression of 
disease (35). These results, combined with the correla­
tion of p53 over expression with increasing grade and 
stage as shown here, imply that p53 overexpression 
plays a role in the progression of bladder cancer.
Analysis of p53 mutations at the molecular genetic 
level is rather difficult and time consuming and there­
fore is not suitable for routine use. IHC, however, is a 
standard technique in pathology laboratories. There is 
a good concordance between p53 mutation and p53 
overexpression in relation to grade, stage and survival, 
so IHC detection of p53 alterations is preferable as a 
predictor of prognosis. Furthermore, IHC might reveal 
anomalies in the p53 pathway other than p53 muta­
tions (see below).
A good concordance between p53 mutation by SSCP 
and p53 overexpression by IHC (p < 0.02) was ob­
served. This strong correlation between high levels of 
p53 protein and mutation in the p53 gene has previ­
ously been described for a number of tumor types, and 
this led to the hypothesis that mutant p53 gene prod­
ucts are characterized by conformational changes of 
the protein, resulting in a higher stability and conse­
quently in accumulation of the protein. However, we
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have observed discrepancies between p53 mutation 
and p53 overexpression.
Of the eight tumors with a p53 mutation as assessed 
by SSCP, two tumors showed no p53 immunoreactivity 
at all. In one tumor, sequence analysis showed a 
transversion in codon 166 of exon 5 generating a stop 
codon and thereby a truncated protein, which does not 
contain the nuclear localization domain at amino acids 
316 to 325 (36). In the other tumor, a deletion of a 
guanine nucleotide found in codon 282 of exon 8 gave 
rise to a frameshift, which also affected the down­
stream nuclear localization sequence. In both cases, 
the loss of the nuclear localization signal most likely 
prevented nuclear accumulation, and therefore IHC 
detection was impossible.
In addition to these “false negatives,” which can still 
be explained by the proposed theory of extended stabi­
lization, we observed p53 over expression in 23% of the 
tumors without any sign of p53 mutation as assessed 
by SSCP. This p53 overexpression without a concomi­
tant mutation was also found in a considerable number 
of bladder tumors in two other studies (37, 38). Al­
though we studied exons 5 to 8, which are known to 
contain the majority of the p53 mutations (1), muta­
tions outside this region and intron mutations might 
explain this result. Moreover, although SSCP is a 
sensitive method for detecting mutations (39), not all 
mutations are detected by this technique. The presence 
of nonneoplastic tissue, although reduced to <30%, can 
lead to a negative SSCP result if the percentage of 
tumor cells overexpressing p53 is approximately 10%. 
This cannot be the explanation for p53 overexpression 
in the 23% of the tumors without a SSCP-proven p53
mutation because most of these tumors contained at 
least 20% of p53 overexpressing tumor cells.
All of the mechanisms leading to p53 overexpression 
are not yet fully understood. According to the already 
mentioned hypothesis, mutant p53 would always be 
stable, and wild-type p53 would be unstable. Thus the 
tight correlation between mutation and overexpression 
could indicate a causal relationship. However, this is 
not always true. In fibroblasts obtained from Li- 
Fraumeni patients who carried heterozygote germ-line 
p53 mutations, the mutant p53 protein did not accu­
mulate to a high level and was unstable like the 
wild-type p53 (40). By contrast, in the tumors of these 
patients, when the wild-type allele was lost, the mu­
tant p53 protein did accumulate. Clearly, p53 mutation 
per se does not cause p53 protein accumulation,
Alternatively, wild-type p53 can accumulate in some 
circumstances, e.g., as a result of complexing with viral 
oncoproteins (16-18) and with the cellular oncoprotein 
mdm2 (20). Accumulation of wild-type p53 in normal 
tissue was shown to occur in a novel cancer family 
syndrome (42). One can hypothesize that anomalies 
elsewhere in the p53 pathway can result in stabiliza­
tion of p53 proteins as well as in the ability to ignore its 
growth-suppressive commands.
We found p53 overexpression in 23% of the cases 
without any sign of a mutation, which is in concor­
dance with two other studies (37, 38), so we suspect 
that some other event(s) in addition to mutation plays 
a role in stabilization. The viral oncoproteins are not 
relevant for the human system. The mdm2 oncoprotein 
has been implicated in the progression of bladder 
cancer (42). Whether mdm2 overexpression represents
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an alternative to p53 mutation in inactivating the p53 
regulatory pathway is still unclear. Events other than 
mutation that lead to stability remain to be elucidated. 
It is noteworthy that p53 can accumulate in normal 
cells upon DNA damage. Thus some tumor cells behave 
as if they were in a permanent state of DNA damage 
(40). Additional research is necessary to characterize 
the signals that trigger this state and to understand 
the mechanisms through which this overexpression 
reflects alteration of p53 function and consequently 
gives rise to an altered phenotype in cancer cells.
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